Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients()

INTRODUCTION: Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). This phase 2, double-blind international trial evaluated the optimal treatment regimen of balapiravir plus peginterferon alfa-2a (4...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Nelson, David R., Zeuzem, Stefan, Andreone, Pietro, Ferenci, Peter, Herring, Robert, Jensen, Donald M., Marcellin, Patrick, Pockros, Paul J., Rodríguez-Torres, Maribel, Rossaro, Lorenzo, Rustgi, Vinod K., Sepe, Thomas, Sulkowski, Mark, Thomason, Isaac R., Yoshida, Eric M., Chan, Anna, Hill, George
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3739984/
https://ncbi.nlm.nih.gov/pubmed/22166557
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki